Home » Authors » Brady Huggett

Articles by Brady Huggett

Alteon's ALT-711 Phase II Misses; Confirmatory Trial Being Planned

July 18, 2003

By Brady Huggett

Alteon's ALT-711 Phase II Misses; Confirmatory Trial Being Planned

July 18, 2003

By Brady Huggett

Several Hybridon Presentations Highlight Early Cancer Platform

July 16, 2003

By Brady Huggett

Several Hybridon Presentations Highlight Early Cancer Platform

July 16, 2003

By Brady Huggett

Titan Presents Pivanex NSCLC Data In Early Combination Trial

July 15, 2003

By Brady Huggett

Titan Presents Pivanex NSCLC Data In Early Combination Trial

July 15, 2003

By Brady Huggett

Immunicon Raises $25M, Eyes Device Revenue Inflow In 2004

July 11, 2003

By Brady Huggett

Immunicon Raises $25M, Eyes Device Revenue Inflow In 2004

July 11, 2003

By Brady Huggett

Genentech's Avastin Rights Outside U.S. Go To Roche

July 9, 2003

By Brady Huggett

Genentech's Avastin Rights Outside U.S. Go To Roche

July 9, 2003

By Brady Huggett

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 28, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 28, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...